National Bank of Canada
ATOS icon

National Bank of Canada’s Atossa Therapeutics ATOS Stock Holding History

National Bank of Canada’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-93
Closed -$1K – 2729
2023
Q1 		$1K Buy
+93
New +$1.04K ﹤0.01% 2530
2022
Q1 		– Sell
-8,740
Closed -$210K – 2850
2021
Q4 		$210K Buy
+8,740
New +$320K ﹤0.01% 1449

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

National Bank of Canada's ATOS Position: Q2 2023 in Review

National Bank of Canada sold out of Atossa Therapeutics (ATOS) in Q2 2023, closing a stake of 93 shares — an estimated $1K sold.

National Bank of Canada first reported a position in ATOS in Q4 2021 and held it in 2 quarters. The position peaked at $210K in Q4 2021. 52 funds tracked by Wall St. Rank hold ATOS as of Q2 2023.

  • National Bank of Canada reported no remaining Atossa Therapeutics position as of Q2 2023 after selling out during the quarter.
  • National Bank of Canada sold 93 Atossa Therapeutics shares in Q2 2023, an estimated $1K.
  • National Bank of Canada first reported a position in Atossa Therapeutics in Q4 2021 and held it in 2 quarters.
  • National Bank of Canada's Atossa Therapeutics position peaked at $210K in Q4 2021.
  • 52 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2023.

Based on National Bank of Canada's 13F filing for Q2 2023, filed 26 Jul 2023.